JP2019529336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529336A5 JP2019529336A5 JP2018566490A JP2018566490A JP2019529336A5 JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5 JP 2018566490 A JP2018566490 A JP 2018566490A JP 2018566490 A JP2018566490 A JP 2018566490A JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- amino acid
- acid sequence
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 claims description 96
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 45
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 36
- 208000028017 Psychotic disease Diseases 0.000 claims description 36
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 35
- 208000034799 Tauopathies Diseases 0.000 claims description 30
- 206010012289 Dementia Diseases 0.000 claims description 29
- 206010002942 Apathy Diseases 0.000 claims description 26
- 208000006011 Stroke Diseases 0.000 claims description 20
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 18
- 206010034010 Parkinsonism Diseases 0.000 claims description 18
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 16
- 208000005400 Synovial Cyst Diseases 0.000 claims description 16
- 230000001054 cortical effect Effects 0.000 claims description 16
- 230000007850 degeneration Effects 0.000 claims description 16
- 230000002490 cerebral effect Effects 0.000 claims description 15
- 210000004940 nucleus Anatomy 0.000 claims description 15
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 13
- 230000009529 traumatic brain injury Effects 0.000 claims description 13
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 12
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 11
- 201000002832 Lewy body dementia Diseases 0.000 claims description 11
- 208000017004 dementia pugilistica Diseases 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 238000011084 recovery Methods 0.000 claims description 10
- 208000014644 Brain disease Diseases 0.000 claims description 9
- 208000032274 Encephalopathy Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 206010039966 Senile dementia Diseases 0.000 claims description 9
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 9
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 9
- 206010014599 encephalitis Diseases 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 8
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 8
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 34
- 102000013498 tau Proteins Human genes 0.000 description 16
- 108010026424 tau Proteins Proteins 0.000 description 16
- 206010037180 Psychiatric symptoms Diseases 0.000 description 12
- 208000020016 psychiatric disease Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 2
- 208000028810 Shared psychotic disease Diseases 0.000 description 2
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 2
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164366A JP7244600B2 (ja) | 2016-07-12 | 2021-10-05 | 過リン酸化タウに特異的な抗体およびその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600416 | 2016-07-12 | ||
| DKPA201600416 | 2016-07-12 | ||
| DKPA201700008 | 2017-01-04 | ||
| DKPA201700005 | 2017-01-04 | ||
| DKPA201700008 | 2017-01-04 | ||
| DKPA201700005 | 2017-01-04 | ||
| DKPA201700179 | 2017-03-14 | ||
| DKPA201700179 | 2017-03-14 | ||
| PCT/EP2017/067067 WO2018011073A1 (en) | 2016-07-12 | 2017-07-07 | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164366A Division JP7244600B2 (ja) | 2016-07-12 | 2021-10-05 | 過リン酸化タウに特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529336A JP2019529336A (ja) | 2019-10-17 |
| JP2019529336A5 true JP2019529336A5 (enExample) | 2021-11-18 |
| JP7029415B2 JP7029415B2 (ja) | 2022-03-03 |
Family
ID=60941665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566490A Active JP7029415B2 (ja) | 2016-07-12 | 2017-07-07 | 過リン酸化タウに特異的な抗体およびその使用方法 |
| JP2021164366A Active JP7244600B2 (ja) | 2016-07-12 | 2021-10-05 | 過リン酸化タウに特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164366A Active JP7244600B2 (ja) | 2016-07-12 | 2021-10-05 | 過リン酸化タウに特異的な抗体およびその使用方法 |
Country Status (41)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012397435B2 (en) | 2012-12-21 | 2017-03-30 | National Institutes For Quantum And Radiological Science And Technology | Novel compound for imaging TAU protein accumulated in the brain |
| EP3303386B1 (en) | 2015-06-05 | 2024-08-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| PH12018502613B1 (en) | 2016-07-12 | 2023-02-01 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| TW202328181A (zh) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
| WO2018127519A1 (en) * | 2017-01-04 | 2018-07-12 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| US11274147B2 (en) * | 2018-02-01 | 2022-03-15 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| JOP20200215A1 (ar) | 2018-03-05 | 2020-09-03 | Janssen Pharmaceutica Nv | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها |
| EP3790883A4 (en) | 2018-05-09 | 2022-08-24 | Aprinoia Therapeutics Limited | Heteroaryl compounds and uses thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12365724B2 (en) | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020193500A1 (en) | 2019-03-28 | 2020-10-01 | H. Lundbeck A/S | Use of a ps396 assay to diagnose tauophaties |
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| WO2021097243A1 (en) | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Inc. | Compounds for degrading tau protein aggregates and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| JPWO2023008415A1 (enExample) | 2021-07-27 | 2023-02-02 | ||
| KR20240049361A (ko) * | 2021-08-25 | 2024-04-16 | 아이바이오, 인크. | 항-cd25 항체 |
| WO2025090817A1 (en) * | 2023-10-24 | 2025-05-01 | Janssen Pharmaceuticals, Inc. | Tau active functional assays |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5102990A (en) | 1989-08-09 | 1992-04-07 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| DK1212422T3 (da) | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
| US20030162230A1 (en) * | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
| US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| JP2009506302A (ja) | 2005-08-04 | 2009-02-12 | イェシバ・ユニバーシティ | Ａｂｌによるタウのリン酸化 |
| JP5525729B2 (ja) | 2005-11-28 | 2014-06-18 | ゲンマブ エー／エス | 組換え一価抗体およびその作製方法 |
| EP2185692A4 (en) | 2007-08-10 | 2012-05-02 | Medarex Inc | HCO32 AND HCO27 AND RELATED EXAMPLES |
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| BR112013008333B1 (pt) * | 2010-10-07 | 2022-10-11 | Ac Immune S.A. | Anticorpo, composição farmacêutica, hibridoma, polinucleotídeo, método de diagnóstico in vitro e usos do anticorpo |
| MX345092B (es) | 2010-10-11 | 2017-01-17 | Univ Zuerich | Anticuerpos anti-tau humanos,. |
| WO2012162179A1 (en) * | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| ES2600915T3 (es) * | 2011-10-07 | 2017-02-13 | Ac Immune S.A. | Anticuerpos fosfoespecíficos que reconocen Tau |
| WO2013151762A1 (en) | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| KR20150036346A (ko) | 2012-07-03 | 2015-04-07 | 워싱턴 유니버시티 | Tau에 대한 항체 |
| EA035976B1 (ru) | 2012-08-16 | 2020-09-08 | АйПИЕРИАН, ИНК. | Анти-tau антитела для лечения таупатий |
| SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
| WO2014170549A1 (en) | 2013-04-16 | 2014-10-23 | Glykos Finland Oy | A method for generating induced pluripotent stem cells |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| KR101838832B1 (ko) | 2014-01-23 | 2018-03-14 | 아사히 가세이 가부시키가이샤 | 블록 공중합체 조성물 및 점접착제 조성물 |
| CN107073297B (zh) | 2014-07-08 | 2021-09-14 | 纽约大学 | Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| PH12018502613B1 (en) | 2016-07-12 | 2023-02-01 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| WO2018127519A1 (en) | 2017-01-04 | 2018-07-12 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
| US10934438B2 (en) | 2017-04-27 | 2021-03-02 | Axalta Coating Systems Ip Co., Llc | Coatings and methods for using and producing the same |
-
2017
- 2017-07-07 PH PH1/2018/502613A patent/PH12018502613B1/en unknown
- 2017-07-07 UA UAA201812547A patent/UA124104C2/uk unknown
- 2017-07-07 AU AU2017295608A patent/AU2017295608B2/en not_active Ceased
- 2017-07-07 EP EP17739940.9A patent/EP3484916B1/en active Active
- 2017-07-07 PE PE2018003304A patent/PE20190227A1/es unknown
- 2017-07-07 JP JP2018566490A patent/JP7029415B2/ja active Active
- 2017-07-07 KR KR1020197001135A patent/KR102551971B1/ko active Active
- 2017-07-07 BR BR112018004916A patent/BR112018004916A2/pt unknown
- 2017-07-07 MA MA056165A patent/MA56165A/fr unknown
- 2017-07-07 EP EP20209554.3A patent/EP3878864A1/en active Pending
- 2017-07-07 RS RS20210397A patent/RS61646B1/sr unknown
- 2017-07-07 CN CN202211523102.2A patent/CN116041504A/zh active Pending
- 2017-07-07 GE GEAP201714957A patent/GEP20217222B/en unknown
- 2017-07-07 RU RU2018143423A patent/RU2760875C1/ru active
- 2017-07-07 TN TNP/2018/000419A patent/TN2018000419A1/en unknown
- 2017-07-07 MY MYPI2018002441A patent/MY197836A/en unknown
- 2017-07-07 SI SI201730686T patent/SI3484916T1/sl unknown
- 2017-07-07 CN CN201780036665.XA patent/CN109618556B/zh active Active
- 2017-07-07 SG SG11201811015RA patent/SG11201811015RA/en unknown
- 2017-07-07 HR HRP20210522TT patent/HRP20210522T1/hr unknown
- 2017-07-07 MA MA45655A patent/MA45655B1/fr unknown
- 2017-07-07 PL PL17739940T patent/PL3484916T3/pl unknown
- 2017-07-07 SM SM20210194T patent/SMT202100194T1/it unknown
- 2017-07-07 NZ NZ748983A patent/NZ748983A/en unknown
- 2017-07-07 CA CA3027561A patent/CA3027561A1/en active Pending
- 2017-07-07 WO PCT/EP2017/067067 patent/WO2018011073A1/en not_active Ceased
- 2017-07-07 PT PT177399409T patent/PT3484916T/pt unknown
- 2017-07-07 LT LTEP17739940.9T patent/LT3484916T/lt unknown
- 2017-07-07 DK DK17739940.9T patent/DK3484916T3/da active
- 2017-07-07 ES ES17739940T patent/ES2862427T3/es active Active
- 2017-07-07 JO JOP/2018/0117A patent/JOP20180117B1/ar active
- 2017-07-07 MX MX2019000476A patent/MX2019000476A/es unknown
- 2017-07-07 HU HUE17739940A patent/HUE053679T2/hu unknown
- 2017-07-10 US US15/645,442 patent/US10472415B2/en active Active
- 2017-07-10 TW TW106123060A patent/TWI747922B/zh active
-
2018
- 2018-12-05 IL IL263530A patent/IL263530B2/en unknown
- 2018-12-10 ZA ZA2018/08329A patent/ZA201808329B/en unknown
- 2018-12-12 DO DO2018000281A patent/DOP2018000281A/es unknown
- 2018-12-28 CO CONC2018/0014325A patent/CO2018014325A2/es unknown
-
2019
- 2019-01-07 SV SV2019005807A patent/SV2019005807A/es unknown
- 2019-01-10 CL CL2019000082A patent/CL2019000082A1/es unknown
- 2019-01-11 NI NI201900003A patent/NI201900003A/es unknown
- 2019-01-24 EC ECSENADI20195417A patent/ECSP19005417A/es unknown
- 2019-04-01 US US16/371,867 patent/US10487142B2/en active Active
- 2019-04-01 US US16/371,902 patent/US10647762B2/en active Active
- 2019-09-27 US US16/585,207 patent/US11111290B2/en active Active
-
2021
- 2021-03-26 CY CY20211100268T patent/CY1123995T1/el unknown
- 2021-08-11 US US17/399,205 patent/US12129289B2/en active Active
- 2021-10-05 JP JP2021164366A patent/JP7244600B2/ja active Active
-
2024
- 2024-03-05 AU AU2024201450A patent/AU2024201450A1/en not_active Abandoned
- 2024-09-24 US US18/895,231 patent/US20250257124A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529336A5 (enExample) | ||
| JP7539446B2 (ja) | 病理学的タウタンパク質の免疫学的標的化方法 | |
| JP7244600B2 (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
| Bussière et al. | Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance | |
| Sigurdsson | Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies | |
| Landlinger et al. | Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease | |
| RU2645259C2 (ru) | Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера | |
| Shahaduzzaman et al. | Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease | |
| Echeverria et al. | Cotinine reduces amyloid-β aggregation and improves memory in Alzheimer's disease mice | |
| RU2657438C2 (ru) | Терапевтическое средство или профилактическое средство против деменции | |
| JP2012522754A5 (enExample) | ||
| JP2018531580A5 (enExample) | ||
| SA520411188B1 (ar) | جسم مضاد مربوط بالفا - ساينوكلين نشط | |
| KR20110011596A (ko) | 아밀로이드증의 치료 및 예방 | |
| Doucet et al. | Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles | |
| JP2016501247A (ja) | 抗Ａβ抗体を使用して脳アミロイド斑を減少させる方法 | |
| JP2015517502A (ja) | 卒中後の神経形成を促進するためのセマフォリン−４ｄ結合分子の使用 | |
| JP6611858B2 (ja) | Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用 | |
| CN104379167B (zh) | 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列 | |
| Wang et al. | Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease | |
| Levigoureux et al. | Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice | |
| Horikoshi et al. | Aβ N-terminal-end specific antibody reduced β-amyloid in Alzheimer-model mice | |
| Li et al. | Novel naturally occurring autoantibodies attenuate α‐synuclein pathology in a mouse model of Parkinson's disease | |
| Gu et al. | Immunotherapy for tauopathies | |
| Kameshima et al. | Correlation of Aβ deposition in the nasal cavity with the formation of senile plaques in the brain of a transgenic mouse model of Alzheimer's disease |